CEO, Executive Chairman Board of Directors
With more than 20 years of industry experience developing and commercializing numerous pharmaceutical drug products and creating significant business value, Michael leads Nanocopoeia with the objective of utilizing company’s proprietary technology to maximize the potential of proven medicines through either ANDA or 505(b)(2) pathways.
Prior to Nanocopoeia, Michael was President and Chief Executive Officer of Paddock Laboratories, a developer, manufacturer and marketer of OTC and specialty brand and generic prescription products from 2007 to July 2011. In less than three years Mike grew the sales of the company from $65 million to over $220 million and successfully completed acquisition transaction to Perrigo for $540 million. Prior to his position with Paddock Laboratories, Mike held multiple leadership positions including President of the Generic Products Division, Par Pharmaceutical 1998 – 2006. He has also held executive positions at two of the country’s largest pharmaceutical distributors. Mike is Chairman of the board of directors for Eagle Pharmaceuticals, and board of directors member of RiboCor, Inc.